Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New european effort matches kids with relapsed leukemia to smarter treatments

NCT ID NCT05270096

Knowledge-focused Sponsor: Princess Maxima Center for Pediatric Oncology Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study helps doctors choose the best available therapy for children and young adults with relapsed or hard-to-treat blood cancers. A team of experts reviews each patient's tumor markers and history to recommend a personalized treatment plan. The study does not give any new drugs but tracks whether doctors follow the advice and how patients do. It aims to improve decision-making and outcomes for these young patients across Europe.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 600 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2022

Expected to finish

Jun 2032

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Children less than 18 years of age at the time of first diagnosis and less than 25 years at the time of inclusion with relapsed/refractory ALL, AML or LBL while being treated in a pediatric/AYA center, and for whom no standard of care treatment is available, and for whom molecular and flow cytometry profiling are available for iLTB discussion, and where the national group supports discussing the patient in the iLTB.

Ages

0 to 25 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria 1. The patient has been diagnosed with a R/R hematological malignancy; 2. The patient is less than 18 years of age at the time of first diagnosis and less than 25 years at the time of inclusion with relapse/refractory hematological malignancy; 3. The patient is treated in a pediatric/AYA setting or study protocol, with no current standard of care treatment; 4. The patients' life expectancy is at least 6 weeks; 5. The patient has undergone any sort of molecular profiling of his/her tumor and the re-sults of this analysis are available; 6. The patient has undergone flow cytometry in a certified lab and results are available; 7. Written informed consent of patient and/or parent(s)/guardian(s) to discuss the patient in the iLTB according to local law and legislation has been obtained. Exclusion criteria: none defined

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Refractory hematologic malignancy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hematopoietic and lymphoid system neoplasm leukemia refractory hematologic cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Refractory hematologic malignancy Relapsed hematologic malignancy

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    7 sites in 7 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Newcastle Hospital

    RECRUITING

    Newcastle, United Kingdom

  • Princess Máxima Center for Pediatric Oncology

    RECRUITING

    Utrecht, Utrecht, 3584CS, Netherlands

  • Queen Silvia

    RECRUITING

    Gothenburg, Sweden

  • Righospitalet

    RECRUITING

    Copenhagen, Denmark

  • Semmelweis

    RECRUITING

    Budapest, Hungary

  • UH Gent

    RECRUITING

    Ghent, Belgium

  • Vall d'Hebron

    RECRUITING

    Barcelona, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.